These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1230 related articles for article (PubMed ID: 21681087)

  • 1. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
    Esteve E; Ricart W; Fernández-Real JM
    Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
    Diamant M; Blaak EE; de Vos WM
    Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
    Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
    Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut microbiota, obesity and insulin resistance.
    Shen J; Obin MS; Zhao L
    Mol Aspects Med; 2013 Feb; 34(1):39-58. PubMed ID: 23159341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics, prebiotics, energy balance, and obesity: mechanistic insights and therapeutic implications.
    Molinaro F; Paschetta E; Cassader M; Gambino R; Musso G
    Gastroenterol Clin North Am; 2012 Dec; 41(4):843-54. PubMed ID: 23101690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH; DiBaise JK; McClain CJ
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota in obesity and metabolic disorders.
    Sanz Y; Santacruz A; Gauffin P
    Proc Nutr Soc; 2010 Aug; 69(3):434-41. PubMed ID: 20540826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential interest of gut microbial changes induced by non-digestible carbohydrates of wheat in the management of obesity and related disorders.
    Neyrinck AM; Delzenne NM
    Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):722-8. PubMed ID: 20823777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding.
    Cani PD; Delzenne NM; Amar J; Burcelin R
    Pathol Biol (Paris); 2008 Jul; 56(5):305-9. PubMed ID: 18178333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota composition and its effects on obesity and insulin resistance.
    Caricilli AM; Saad MJ
    Curr Opin Clin Nutr Metab Care; 2014 Jul; 17(4):312-8. PubMed ID: 24848531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.
    Bekkering P; Jafri I; van Overveld FJ; Rijkers GT
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1031-41. PubMed ID: 24138599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal microbiota in inflammation and insulin resistance: relevance to humans.
    De Bandt JP; Waligora-Dupriet AJ; Butel MJ
    Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):334-40. PubMed ID: 21587065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance.
    Escobedo G; López-Ortiz E; Torres-Castro I
    Rev Invest Clin; 2014; 66(5):450-9. PubMed ID: 25695388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota and type 2 diabetes mellitus.
    Muñoz-Garach A; Diaz-Perdigones C; Tinahones FJ
    Endocrinol Nutr; 2016 Dec; 63(10):560-568. PubMed ID: 27633134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and the human microbiome.
    Ley RE
    Curr Opin Gastroenterol; 2010 Jan; 26(1):5-11. PubMed ID: 19901833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut decontamination with norfloxacin and ampicillin enhances insulin sensitivity in mice.
    Chou CJ; Membrez M; Blancher F
    Nestle Nutr Workshop Ser Pediatr Program; 2008; 62():127-37; discussion 137-40. PubMed ID: 18626197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk.
    Miele L; Giorgio V; Alberelli MA; De Candia E; Gasbarrini A; Grieco A
    Curr Cardiol Rep; 2015 Dec; 17(12):120. PubMed ID: 26497040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.